Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est
Benzinga Newsdesk 3 weeks ago
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927 billion vs $21.143
Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927 billion vs $21.143 billion estimate.
More on BSX
Benzinga
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 YearsBoston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 2.14% on an annualized basis producing an average annual return of 15.02%. Currently, Boston Scientific has a market…

